Caliway Biopharmaceuticals Co., Ltd. (6919)
TWSE
611.00
+10.00 (+1.66%)
Closed
Dec 2, 2024
Day's Range
592.00628.00
52 wk Range
240.50800.00
Financial Statements - 6919 - Caliway Biopharmaceuticals Co., Ltd.
Revenue
38.93M
Net Income
-488.45MNet Margin -1254.6%
EBITDA
-460.09M
Free Cash Flow
-433.62M
Income Statement
| Period Ending | 2023-12-31 |
|---|---|
| Sales | 38.93M |
| Cost of Goods | 11.46M |
| Gross Profit | 27.46M |
 Operating Expense | - |
| Operating Income | -513.46M |
| Non-Operating Interest | - |
| Other Income Expense | - |
| Pre Tax Income | -488.45M |
| Income Tax | 0 |
| Net Income | -488.45M |
| EPS Basic | -3.94 |
| EPS Diluted | -3.94 |
| Basic Shares Outstanding | 123.88M |
| Diluted Shares Outstanding | 123.88M |
| Ebit | -487.95M |
| Ebitda | -460.09M |
| Net Income Continuous Operations | -488.45M |
| Minority Interests | - |
| Preferred Stock Dividends | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
